We will present our researches on the importance of ECM for drug discovery in Parkinson’s disease at NeuroFrance congress (May 19 to 21 )

The international NeuroFrance congress will take place May, 19, 20 and 21th 2021 (virtual meeting). On this occasion, our PhD student Véronique De Conto will present these works in a poster about the importance of matricial and cellular microenvironment for drug discovery in Parkinson’s disease (summary below). Feel free to Read more…

Impact of neurodegenerative diseases on extracellular space organization and diffusion through hyaluronan remodeling

Soria et al. has published this year an interesting study about the modification leading by synucleopathy on the nanoscale organization and diffusivity of the extracellular space, through hyaluronan remodeling. Indeed the extracellular space (ECS), composed by the interstitial fluid and the extracellular matrix (ECM), plays several roles in health and Read more…

3D co-culture of dopaminergic neurons and astrocytes in BIOMIMESYS® Brain to study Parkinson’s disease

Parkinson’s disease affects more than 6 million people worldwide. This neurodegenerative disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta, with intracellular accumulation of alpha-synuclein aggregates known as Lewi bodies. This neuronal loss leads to a decrease in the neurotransmitter dopamine that cause mainly Read more…

Feedback from SCMC congress: Maturation and Development of Cerebrovascular System

The annual SCMC congress (Société Cerveau et Maladies Cérébrovasculaires – Brain and Cerebrovascular diseases Society) took place in Lille last week, in the Faculty of Medecine. The congress was organized in three sessions. The first session was about cerebrovascular development and maturation. The conferences began with a lecture about blood-brain Read more…

Direct Effect of Bevacizumab on Glioblastoma Cell Lines In Vitro

Abstract  Bevacizumab is a humanized monoclonal antibody directed against the pro-angiogenic factor vascular and endothelial growth factor-A (VEGF-A) used in the treatment of glioblastomas. Although most patients respond initially to this treatment, studies have shown that glioblastomas eventually recur. Several non-mutually exclusive theories based on the anti-angiogenic effect of bevacizumab Read more…